Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retrospective Study Evaluating the Relationship between Early Changes in Disease Specific Light Chains and Depth/Duration of Hematologic Responses in Amyloidosis Patients Treated with Daratumumab

Trial Profile

A Retrospective Study Evaluating the Relationship between Early Changes in Disease Specific Light Chains and Depth/Duration of Hematologic Responses in Amyloidosis Patients Treated with Daratumumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jul 2018

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone
  • Indications Amyloid light-chain amyloidosis
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 29 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top